BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics (NASDAQ:MNPR) had its price target lifted by analysts at BTIG Research from $117.00 to $133.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price target points to a potential upside of 15.87% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the company. HC Wainwright boosted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Monopar Therapeutics has a consensus rating of “Buy” and a consensus price target of $113.42.

Monopar Therapeutics Trading Up 0.3%

Shares of NASDAQ:MNPR traded up $0.32 during mid-day trading on Wednesday, reaching $114.78. The company had a trading volume of 306,811 shares, compared to its average volume of 222,083. Monopar Therapeutics has a one year low of $29.18 and a one year high of $124.82. The company’s 50-day moving average price is $92.93 and its 200-day moving average price is $70.68. The firm has a market cap of $768.91 million, a price-to-earnings ratio of -60.41 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Wednesday, August 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). On average, research analysts anticipate that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of MNPR. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics in the third quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its stake in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $65,000. Caitong International Asset Management Co. Ltd bought a new position in Monopar Therapeutics in the 4th quarter valued at $86,000. Finally, JPMorgan Chase & Co. boosted its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the period. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.